Search results

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Accelerate therapeutic discovery and maximize ROI with our streamlined platform, fully integrated across your entire portfolio. Use digital and decentralized trials to scale your pipeline beyond what's possible with traditional clinical trials.

Join leading clinical experts as they discuss and debunk the top 5 myths about eCOA in 2025, separating fact from fiction to help clinical operations, procurement, and data management teams make smarter, faster decisions.

Explore the prevalent challenges encountered in eCOA clinical trials, from technical issues and patient adherence to data security and regulatory adherence, and discover strategies for mitigation.

With MarketsandMarkets projecting the global electronic Clinical Outcome Assessments (eCOA) solutions market to grow at compound annual growth rate (CAGR) of 16.1% each year until 2030, it’s clear the eCOA has made its impact within the clinical research landscape. Yet despite growing adoption, electronic Clinical Outcome Assessments (eCOA) are still surrounded by misconceptions that hinder their full potential. From concerns about patient usability to assumptions about cost and implementation timelines, these myths can create hesitation among sponsors and research teams alike.Thus, we’re here to cut through the noise and set the record straight with a summary of a recent webinar featuring speakers from Transcelerate and Medable.

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

With the 14th annual DPHARM® wrapping up, we talked to our peers across the industry to find out what the big themes and takeaways were from this year’s conference.

Gain a quick overview of what top trends and topics dominated DIA 2023.

Discover how Medable helped digitize and standardize a client's participant pain body maps for a diabetic polyneuropathy trial.

See why the electronic clinical outcome (eCOA) market is poised to continue its rapid growth and why Medable customers have chosen eCOA as a future foundation for their next era of clinical conduct.

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

Learn what impacts the new European Medicine Regulatory Network recommendations paper means to your clinical trial operations.

As 2022 rounds the bend, the life science industry is at a critical juncture in the adoption of the decentralized clinical trial (DCT) model.

Regain control and stay competitive with Medable Studio—your all-in-one platform to build and launch protocol-fit digital solutions for your customers.

See why many of the top pharma are focused on building the "next model" of clinical trial conduct using foundational platforms.

Medable's CRO Partner Program equips you with advanced GenAI and automation tools to accelerate clinical trial builds, streamline data collection, and offer flexible service tiers tailored to your operational needs. Empower your studies and win more business.

Learn how Medable's eCOA (electronic clinical outcome assessment) solution was able to deliver >90% adherence and scalability for a top pharmaceutical weight management clinical trial.

Contact Medable for a demo and to learn more about DCT certification, careers, and support. Medable, per Everest Group Peak matrix, is the top decentralized clinical trial company.

Discover how Medable is revolutionizing clinical trials with faster enrollment, more control and transparency, and patient-first solutions. Learn how we’re expanding access to life-changing treatments globally, driving innovation, and transforming operations for better outcomes in clinical research.

Gain an overview of how artificial intelligence (AI) and machine learning (ML) can transform clinical trials from start to finish.

Medable’s Privacy Statement applies to your use of the Medable.com websites (the “Sites”) as well as certain Medable Services (the “Services”).

A top 10 pharmaceutical company looked to Medable to streamline participant burden and enhance site and team experience in oncology trials, while establishing a scalable template for future trials in oncology and other areas.

See how customers have had success with Medable, our trial platform, and our teams.

Streamline your clinical trial and generate high-quality data with a #1 rated, easy-to-use platform, offered in over 60 countries and 120 languages. Book a demo to learn more.

Learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.

A top-3 contract research organization (CRO) and a top-10 pharmaceutical company partnered with Medable to help accelerate the speed, scale, and standardization of their eCOA trials.The two organizations had been hampered by lengthy configuration timelines, inconsistent designs across studies, and siloed processes between sponsors and their CRO partners.By centralizing the sponsor’s preferred instruments and configurations into a reusable digital library, Medable enabled the CRO to rapidly accelerate its portfolio development and initiate new studies without starting them “from scratch.”‍

Gain a quick summary of what the 2023 EU Regulatory Recommendations for Decentralized Trials mean.

Join Medable's Mohammed Ali, Chief Domain Expert and Shubha Govil, SVP of Product Management,Platform to hear how top pharma teams have adopted digital technology across a platform to reduce costs and accelerate time to market.

Medable worked with a top 5 pharma company to increase the safety of patients as anti-cancer treatments may cause pulmonary toxicity, ranging from asymptomatic radiological changes to respiratory failure, and is considered a common side effect.

In this webinar, learn how top pharma are using novel innovations to drive greater speed, scale, and access in clinical research than ever before in this webinar hosted by Musaddiq Khan, Vice President of DCT Solutions at Medable.

Learn how we can help you navigate the complexities of clinical operations so that you can meet your study's milestones faster and easier.

A top-10 global pharmaceutical company aimed to address eCOA adherence and patient enrollment challenges faced by clinical trial sites and participants in Japan. Recognizing Japan’s distinct regulatory, cultural, and logistical landscape, the company partnered with Medable to develop an initiative to enhance the region’s patient and site experience.

At DIA 2025, this year's conference underscored key themes that are shaping the landscape of medical product development, with Artificial Intelligence (AI) and Real-World Data (RWD) taking center stage.

A top, global clinical research organization (CRO) partnered with Medable to transform its approach to clinical trial building. Recognizing the inefficiencies in traditional build processes that often “take weeks,” the client leveraged Medable’s Studio platform with its latest AI capabilities to dramatically accelerate timelines, enhance transparency, and improve quality. ‍‍

See how Medable was able to increase study startup speed for one customer by 50%.

See how Medable helped one customer achieve their fastest enrollment ever.

The partnership between Medable, U.S. Renal Care, and the top ten pharmaceutical sponsor exemplifies the transformative power of Medable’s Total Consent solution in clinical trials. By overcoming common misconceptions around participant age, cost, and complexity, Medable’s platform proved to be a flexible, fast, and efficient solution for the elderly renal care population. U.S. Renal Care sought to use Medable’s Total Consent (Medable’s eConsent solution) for an investigator-initiated trial. The phase 4 trial, which was funded by a top 10 pharmaceutical company, sought to enroll elderly participants suffering from Anemia ESKD (End Stage Kidney Disease) across 476 site users. The trial would be managed by three central principal investigators (PIs).